### Research Areas

<table>
<thead>
<tr>
<th>Area</th>
<th>Sub-areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tool Development</td>
<td>Data Sharing</td>
</tr>
<tr>
<td>Biomarker Research</td>
<td>Disease Progression</td>
</tr>
<tr>
<td>Basic Research</td>
<td></td>
</tr>
<tr>
<td>Data-Sharing Enabler</td>
<td></td>
</tr>
</tbody>
</table>

### At a Glance

- **Status:** Active Consortium
- **Year Launched:** 2009
- **Initiating Organization:** The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Initiator Type:** Academia
- **Location:** North America

### Abstract

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the CKD Biomarkers Consortium (BioCon) to promote the discovery and validation of biomarkers to advance the field of chronic kidney disease (CKD) research. The NIDDK CKD Biomarkers Consortium brings together investigators whose expertise includes clinical nephrology, epidemiology, molecular biology, genomics, proteomics, metabolomics, systems biology, laboratory medicine, biostatistics, and laboratory test verification and qualification.

### Mission

BioCon is a collaborative effort involving numerous investigators from multiple institutions working together to pursue the development and validation of novel biomarkers for CKD by assaying biological
specimens and utilizing data from the nation’s largest epidemiological studies of kidney disease. Studies conducted by the CKD BioCon assay biospecimens and analyze data from various epidemiological studies of kidney disease that were previously conducted by the NIDDK, such as the AASK, MDRD, ARIC, CRIC, DCCT/EDIC cohorts, and more. Specific aims vary by study, but include identifying and evaluating biomarkers of CKD incidence, cardiovascular events, changes in kidney histology, and disease progression and outcomes. The development and validation of biomarkers that results from these studies will aid in the identification of high-risk patients and inform clinical practices for monitoring and treatment of individuals with CKD.

The CKD Biomarkers Consortium was established to pursue the discovery and validation of novel biomarkers for CKD to advance research into the causes and outcomes of the disease.

**Consortium History**

Phase I of BioCon began in 2009 and will continue into 2016. Phase II of BioCon began in July 2015 with a reconstituted set of investigators and scientific activities.

**Financing**

The phases of the program are financed via grants by the Department of Health and Human Services and other organizations.

**Impact/Accomplishment**

**CKD Biomarkers Consortium Publications**

**Links/Social Media Feed**
Points of Contact

Investigators interested in collaborating with the CKD Biomarkers Consortium should contact:

Krista Whitehead, MS
Research Project Manager
Perelman School of Medicine
at The University of Pennsylvania
kristaw@mail.med.upenn.edu

Sponsors & Partners

For a list of participating partners, click here

Updated: 06/19/2017